ストックスクリーナーアプリを入手
1.22
19.74%
-0.30
アフターアワーズ：
1.22
前日終値:
$1.52
開ける：
$1.41
24時間の取引高:
435.48K
Relative Volume:
0.93
時価総額：
$78.14M
収益：
-
当期純損益:
$-45.08M
株価収益率:
-1.6712
EPS:
-0.73
ネットキャッシュフロー:
$-33.68M
1週間 パフォーマンス:
-26.06%
1か月 パフォーマンス:
-22.29%
6か月 パフォーマンス:
-55.64%
1年 パフォーマンス:
-48.95%
1日の値動き範囲:
$1.19
$1.41
1週間の範囲:
$1.19
$1.8207
52週間の値動き範囲:
$0.726
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
名前
Galectin Therapeutics Inc
セクター
電話
678-620-3186
住所
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
GALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.22 | 78.14M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-08-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-13 | 開始されました | B. Riley FBR | Buy |
| 2017-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-19 | 開始されました | ROTH Capital | Buy |
| 2017-03-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | ダウングレード | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | ダウングレード | ROTH Capital | Buy → Sell |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-09-21 | 開始されました | H.C. Wainwright | Buy |
| 2014-08-01 | ダウングレード | Aegis Capital | Buy → Hold |
| 2014-07-30 | 繰り返されました | MLV & Co | Buy |
| 2014-07-29 | 繰り返されました | MLV & Co | Buy |
| 2014-04-02 | 繰り返されました | MLV & Co | Buy |
| 2014-02-10 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-09 | 繰り返されました | Aegis Capital | Buy |
| 2013-12-03 | 開始されました | MLV & Co | Buy |
| 2013-08-19 | 繰り返されました | Aegis Capital | Buy |
すべてを表示
Galectin Therapeutics Inc (GALT) 最新ニュース
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World
PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World
Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St
Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance
Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Updates Investors on Clinical Trials - TipRanks
Galectin Therapeutics shareholders elect directors, ratify auditor - MSN
Galectin Therapeutics Inc. Reports Positive Additional Results from NAVIGATE TrialOn February 18, 2025, Galectin Therapeutics Inc. (NASDAQ: GALT) announced significant findings from the NAVIGATE trial regarding belapectin, its therapeutic focus on ta - Defense World
Galectin Therapeutics’ belapectin shows reduction in new varices - TipRanks
Galectin Reports 68% Reduction In New Varices With Belapectin In NAVIGATE Trial U.S. Cohort - Nasdaq
Galectin Therapeutics IncReports Significant Reduction In New Varices With Belapectin - Marketscreener.com
Belapectin shows promise in MASH cirrhosis trial - Investing.com India
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com South Africa
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial - The Manila Times
Major Breakthrough: Galectin's MASH Treatment Cuts Liver Complications by 68% in Latest Trial Data - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Stratos Wealth Partners LTD. - Defense World
Largest borrow rate increases among liquid names - MSN
JPMorgan Chase & Co. Grows Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight - The Malaysian Reserve
Liver Cirrhosis Market Forecasted for Strong Growth from 2025 - openPR
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Galectin drops as trial for lead asset fails in MASH - MSN
Galectin Therapeutics shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ: GALT) 8-K Filing Reveals Positive Results from NAVIGATE Trial - Defense World
Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Unveils Promising NAVIGATE Trial Results - TipRanks
HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN
Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
SouthState Corporation Announces Sale Agreement with Blue Owl Real Estate Capital On January 8, 2025, SouthState Bank, N.A., a subsidiary of SouthState Corporation, has entered into a significant agreement for the purchase and sale of real property w - Defense World
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat
Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times
Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World
Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria
Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL
Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Sanctuary Advisors LLC - Defense World
Galectin Therapeutics Inc (GALT) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):